The tender offer has not yet commenced. Watch for the Schedule TO filing and CFIUS declaration — any delay or CFIUS intervention would be the primary risk to closing. The 90% minimum tender condition means institutional or large-block holder support is critical.
Price Chart
Executive Summary
Cavitation Technologies (CVAT) entered into a definitive tender offer agreement with BrightFlixx Finance (Luxembourg) S.A., replacing a prior agreement with European Guarantee Services. BrightFlixx will acquire all CVAT shares for $35 million in cash (less liabilities), implying an initial estimated price of $0.106 per share. Concurrently, BrightFlixx will acquire Alchemy Beverages (in which CVAT holds 17%) for $7 million. The offers are cross-conditioned and subject to CFIUS approval and 90% minimum tender conditions.
Key Financial Metrics
Key Facts
- BrightFlixx to acquire all CVAT shares for $35 million cash, less liabilities
- Initial estimated offer price: $0.106 per share based on $738,000 liabilities and 323,820,459 shares outstanding
- Concurrent acquisition of Alchemy Beverages for $7 million cash, less liabilities
- Offers are cross-conditioned — each requires the other to close simultaneously
- Conditions include 90% minimum tender, CFIUS clearance, and no material adverse change
- Prior EGS agreement terminated without any termination fee
- Same financing institution (Bright Wealth Banking) involved as in prior transaction
- Offer period: 60 business days initially, extendable; final price determined 45 business days after commencement
- Company board unanimously recommends the offer
- End date for closing: June 30, 2027
Financial Impact
All-cash acquisition of CVAT at $35 million (net of ~$738K liabilities) and Alchemy at $7 million, aggregate $42 million
Risk Factors
- CFIUS review could block or delay the transaction given the foreign acquirer (Luxembourg entity)
- 90% minimum tender condition may not be met if shareholders hold out for a higher price
- Cross-conditionality with Alchemy offer adds execution risk — if Alchemy deal fails, CVAT deal fails
- No termination fee protects CVAT if BrightFlixx fails to secure financing
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007778 |
| Document: cavitation_8k.htm | 0001683168-26-007778 |
| Document: cavitation_ex9901.htm | 0001683168-26-007778 |
| Document: 0001683168-26-007778-index-headers.html | 0001683168-26-007778 |
| Document: 0001683168-26-007778-index.html | 0001683168-26-007778 |
| Document: 0001683168-26-007778.txt | 0001683168-26-007778 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | SC TO-T | $0.0400 | awaiting T+5 | — | $0.0300 (−25.00%) |
Oct 13, 2026 14d ago | 8-K | $0.0300 $0.0300 | · 0.00% | ▲ +1.15% | $0.0300 (−0.00%) |
Sep 28, 2026 28d ago | NT 10-K | $0.0400 $0.0400 | · 0.00% | ▲ +1.20% | $0.0300 (+25.00%) |
Aug 19, 2026 9w ago | 8-K | $0.0400 $0.0443 | ▲ +10.75% | ▲ +11.14% | $0.0300 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers